Related Experiment Videos

ACTH-receptor deficient mutants of the Y1 mouse adrenocortical tumor cell line

B P Schimmer1, W K Kwan, J Tsao

  • 1Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.

Endocrine Research
|February 1, 1995
PubMed

Insights

Two mouse adrenocortical tumor cell clones resistant to ACTH lack ACTH receptor transcripts. This ACTH receptor gene defect is reversible, suggesting a modified gene expression underlies hormone resistance.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Cell Biology

Background:

  • Y1 mouse adrenocortical tumor cells are responsive to ACTH.
  • Mutant clones Y6 and OS3 exhibit resistance to ACTH.
  • This resistance is characterized by a lack of adenylyl cyclase activation and steroidogenesis.

Purpose of the Study:

  • To investigate the molecular basis of ACTH resistance in Y1 mouse adrenocortical tumor cell mutants.
  • To determine if the ACTH receptor gene is present and functional in these resistant clones.

Main Methods:

  • Northern blot and RNase protection assays to analyze ACTH receptor transcript levels.
  • Southern blot hybridization to assess the presence of the ACTH receptor gene.
  • Cellular transformation with a beta 2-adrenergic receptor gene to assess adenylyl cyclase system integrity.

Main Results:

  • Mutant clones Y6 and OS3 failed to accumulate ACTH receptor transcripts.
  • The ACTH receptor gene was detected in mutants, suggesting a reversible modification.
  • Transformed mutants responded normally to beta-adrenergic agonists, indicating an intact adenylyl cyclase system.

Conclusions:

  • ACTH resistance in Y6 and OS3 clones is due to a failure in ACTH receptor transcript accumulation.
  • The ACTH receptor gene modification is reversible.
  • The adenylyl cyclase system remains functional, with transcript deficiency limiting hormone responsiveness.

Related Concept Videos